1
|
Salehzadeh F, Esmkhani M, Zallaghi M, Javanshir S, Dekamin MG. CuFe 2O 4@SiO 2@L-arginine@Cu(I) as a new magnetically retrievable heterogeneous nanocatalyst with high efficiency for 1,4-disubstituted 1,2,3-triazoles synthesis. Sci Rep 2023; 13:8675. [PMID: 37248371 DOI: 10.1038/s41598-023-36012-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2022] [Accepted: 05/27/2023] [Indexed: 05/31/2023] Open
Abstract
A novel magnetic heterogeneous catalyst was synthesized through the immobilization of copper ions onto the l-arginine functionalized CuFe2O4@SiO2. The prepared catalyst was characterized by Fourier Transform Infrared (FT-IR), X-ray diffraction (XRD), Field emission scanning electron microscopy (FE-SEM), Transmission electron microscopy (TEM), and Energy Dispersive X-Ray spectroscopy (EDX). The resulting catalyst was used in the ultrasonic-assisted synthesis of 1,2,3-triazoles via a one-pot three-component reaction of alkynes, alkyl halides, and sodium azides under green conditions within a short time. The catalyst reusability was investigated after five cycles and no significant loss of activity was observed.
Collapse
Affiliation(s)
- Fatemeh Salehzadeh
- Pharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Iran
| | - Maryam Esmkhani
- Pharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Iran
| | - Mahsa Zallaghi
- Pharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Iran
| | - Shahrzad Javanshir
- Pharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Iran.
| | - Mohammad G Dekamin
- Pharmaceutical and Heterocyclic Compounds Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran, 16846-13114, Iran
| |
Collapse
|
2
|
Baghersad MH, Maleki A, Khodabakhshi MR. Design and development of novel magnetic Lentinan/PVA nanocomposite for removal of diazinon, malathion, and diclofenac contaminants. JOURNAL OF CONTAMINANT HYDROLOGY 2023; 256:104193. [PMID: 37229922 DOI: 10.1016/j.jconhyd.2023.104193] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Revised: 04/22/2023] [Accepted: 04/25/2023] [Indexed: 05/27/2023]
Abstract
Increasing population growth and rapid expansion of the industrialization of the world society have caused severe environmental pollution to the planet. This study was carried out in order to investigate the synthesis of biopolymeric texture nano adsorbent based on the Lentinan (LENT), Poly Vinyl Alcohol (PVA) and Iron Oxide nanoparticles for the removal of environmental pollutants. The spherical structural morphology of Fe3O4@LENT/PVA nanocomposite has been determined by FE-SEM analyses. According to the obtained results from FTIR analyses, all absorption bands of the Fe3O4, LENT, and PVA, had been existed in nanocomposite and approved the successful formation of it. From EDS analysis, it has been revealed that 57.21 wt% Fe, 17.56 wt% C and 25.23 wt% O. Also, the XRD pattern of the nanocomposite, approved the presence of polymeric and magnetic parts with card no. JCPDS, 01-075-0033. The BET analysis has defined specific surface area (47 m2/g) and total pore volume (0.15 cm3/g). Moreover, high heterogeneity and structural stability of the fabricated Fe3O4@LENT/PVA nanocomposite have been proven by TGA. Besides, VSM analysis measured great magnetic property of the nanocomposite (48 emu/g). Also, the Fe3O4@LENT/PVA nanocomposite potential for effective removal of malathion (MA), Diazinon (DA), and Diclofenac (DF) from watery solution has studied by an experiment based on the efficacy of adsorbent dosage, pH, and temperature. The adsorption kinetics of three pollutants had investigated using pseudo-first-order (PFO), pseudo-second-order (PSO) and intra-particle diffusion (IPD) velocity equations, the results showed that the kinetics followed PSO velocity equations. Also, the Langmuir, Freundlich, Dubbin-Radushkevich (D-R) and Temkin isotherm models had investigated, and the adsorption isotherm was adopted from the Langmuir model. The results demonstrated that in the presence of Fe3O4@LENT/PVA nanocomposite, at the optimal conditions (contact time = 180 min, pH = 5, nanocomposite dosage = 0.20 g/L and temperature of 298 K) the maximum adsorption capacity of MA, DF, and DA were 101.57, 153.28, and 102.75 mg/g, respectively. The antibacterial features of the Fe3O4@LENT/PVA nanocomposite, had evaluated by Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) bacteria, but the result did not show any antibacterial activity.
Collapse
Affiliation(s)
- Mohammad Hadi Baghersad
- Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Vanak Square, Mollasadra Ave, P.O. Box 19945-546, Tehran, Iran.
| | - Ali Maleki
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology, 16846-13114 Tehran, Iran.
| | - Mohammad Reza Khodabakhshi
- Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Vanak Square, Mollasadra Ave, P.O. Box 19945-546, Tehran, Iran.
| |
Collapse
|
3
|
Shinde G, Thakur J. Core-shell structured Fe3O4@MgO: magnetically recyclable nanocatalyst for one-pot synthesis of polyhydroquinoline derivatives under solvent-free conditions. J CHEM SCI 2023. [DOI: 10.1007/s12039-023-02134-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
|
5
|
González A, Casado J, Gündüz MG, Santos B, Velázquez-Campoy A, Sarasa-Buisan C, Fillat MF, Montes M, Piazuelo E, Lanas Á. 1,4-Dihydropyridine as a Promising Scaffold for Novel Antimicrobials Against Helicobacter pylori. Front Microbiol 2022; 13:874709. [PMID: 35694298 PMCID: PMC9174938 DOI: 10.3389/fmicb.2022.874709] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2022] [Accepted: 05/03/2022] [Indexed: 12/19/2022] Open
Abstract
The increasing occurrence of multidrug-resistant strains of the gastric carcinogenic bacterium Helicobacter pylori threatens the efficacy of current eradication therapies. In a previous work, we found that several 1,4-dihydropyridine (DHP)-based antihypertensive drugs exhibited strong bactericidal activities against H. pylori by targeting the essential response regulator HsrA. To further evaluate the potential of 1,4-DHP as a scaffold for novel antimicrobials against H. pylori, we determined the antibacterial effects of 12 novel DHP derivatives that have previously failed to effectively block L- and T-type calcium channels. Six of these molecules exhibited potent antimicrobial activities (MIC ≤ 8 mg/L) against three different antibiotic-resistant strains of H. pylori, while at least one compound resulted as effective as metronidazole. Such antimicrobial actions appeared to be specific against Epsilonproteobacteria, since no deleterious effects were appreciated on Escherichia coli and Staphylococcus epidermidis. The new bactericidal DHP derivatives targeted the H. pylori regulator HsrA and inhibited its DNA binding activity according to both in vitro and in vivo analyses. Molecular docking predicted a potential druggable binding pocket in HsrA, which could open the door to structure-based design of novel anti-H. pylori drugs.
Collapse
Affiliation(s)
- Andrés González
- Group of Translational Research in Digestive Diseases, Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain
- Department of Medicine, Psychiatry and Dermatology, University of Zaragoza, Zaragoza, Spain
- Institute for Biocomputation and Physics of Complex Systems (BIFI), Zaragoza, Spain
- Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain
- *Correspondence: Andrés González,
| | - Javier Casado
- Group of Translational Research in Digestive Diseases, Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain
- Department of Biochemistry and Molecular and Cellular Biology, University of Zaragoza, Zaragoza, Spain
| | - Miyase Gözde Gündüz
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
| | - Brisa Santos
- Department of Biochemistry and Molecular and Cellular Biology, University of Zaragoza, Zaragoza, Spain
| | - Adrián Velázquez-Campoy
- Institute for Biocomputation and Physics of Complex Systems (BIFI), Zaragoza, Spain
- Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain
- Department of Biochemistry and Molecular and Cellular Biology, University of Zaragoza, Zaragoza, Spain
- Fundación Agencia Aragonesa para la Investigación y el Desarrollo (ARAID), Zaragoza, Spain
| | - Cristina Sarasa-Buisan
- Institute for Biocomputation and Physics of Complex Systems (BIFI), Zaragoza, Spain
- Department of Biochemistry and Molecular and Cellular Biology, University of Zaragoza, Zaragoza, Spain
| | - María F. Fillat
- Institute for Biocomputation and Physics of Complex Systems (BIFI), Zaragoza, Spain
- Department of Biochemistry and Molecular and Cellular Biology, University of Zaragoza, Zaragoza, Spain
| | - Milagrosa Montes
- Department of Microbiology, Donostia University Hospital-Biodonostia Health Research Institute, San Sebastian, Spain
- Biomedical Research Networking Center in Respiratory Diseases (CIBERES), Madrid, Spain
| | - Elena Piazuelo
- Group of Translational Research in Digestive Diseases, Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain
- Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain
- Aragón Health Sciences Institute (IACS), Zaragoza, Spain
| | - Ángel Lanas
- Group of Translational Research in Digestive Diseases, Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain
- Department of Medicine, Psychiatry and Dermatology, University of Zaragoza, Zaragoza, Spain
- Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain
- Digestive Diseases Service, University Clinic Hospital Lozano Blesa, Zaragoza, Spain
| |
Collapse
|